News | October 12, 2021
Everest Organics develops API for molnupiravir
The drug is being developed at lab scale for the first-line of treatment of Covid-19
The drug is being developed at lab scale for the first-line of treatment of Covid-19
_256_384.jpg)
The two doses of Covaxin are likely to be administered to children with a gap of 28 days
It is one of the first companies to launch a bioequivalent version of the dry powder inhaler and it's part of the company’s strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and the UK
AZD7442 reduced risk of developing severe Covid-19 or death in Tackle Phase III outpatient treatment trial
The Pune centre expands its presence beyond Bangalore and Hyderabad
The company will shift 100 percent of its energy use to renewable sources for both power and heat by 2025 in order to achieve carbon neutrality
The test kit uses a reagent developed using Kaneka's molecular testing-related technologies
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
Quantitative restrictions in place to meet domestic needs to cater to the vaccination programme
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
Subscribe To Our Newsletter & Stay Updated
